Based on the monthly dosing efficacy and tolerability demonstrated in this trial, we remain confident in our plan to include a higher 9.6-milligram monthly maintenance dose of PF3944 in Phase 3. The drug was made by developer Metsera, which Pfizer acquired in a bidding war with competitor Novo Nordisk last year
The glucagon receptor component promotes lipid mobilization specifically from adipose tissue, which contributes to improved metabolic markers beyond what the scale shows
Meals may feel more satisfying
Outside these cities, the picture changes
After beginning at the starting dose, should additional clinical effects be needed, your doctor may recommend increasing to the next highest tirzepatide dose at 4-week intervals
The goal isnt to achieve circus-performer flexibility, but to maintain a healthy range of motion in your joints and prevent stiffness